Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: A phase I/II trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 6, 2006, Pages 576-582

  Schoppmeyer, Konrad ^a   Miethe, Susanne ^a   Wiedmann, Marcus ^a   Liebmann, Andre ^a   Hauss, Johann ^a   Mossner, Joachim ^a   Caca, Karel ^b   Witzigmann, Helmut ^a   Hildebrandt, Guido ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b KLINIKUM LUDWIGSBURG   (Germany)

Author keywords

Adjuvant therapy; Extrahepatic bile duct cancer; Radiochemotherapy; Toxicity

Indexed keywords

CAPECITABINE; GEMCITABINE;

ABDOMINAL CRAMP; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; BILE DUCT CARCINOMA; BILIARY TRACT DRAINAGE; BLOOD TOXICITY; CACHEXIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLANGITIS; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DUODENUM ULCER; EDEMA; ENDOSCOPIC SURGERY; FATIGUE; FEMALE; FLATULENCE; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HUMAN; JAUNDICE; LAPAROTOMY; LEUKOPENIA; LYMPH NODE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; RADIATION DOSE FRACTIONATION; SEPTIC SHOCK; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33845496517     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000239167.17922.82     Document Type: Conference Paper

References (34)

1. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995;75(Suppl):171-190.
2. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumours. Ann Surg. 1996;224:463-473.
3. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001;234:507-519.
4. Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg. In press.
5. Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005;241:77-84.
6. Fong Y, Blumgart LH, Lin E, et al. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996;83:1712-1715.
7. Neuhaus P, Jonas S, Bechstein WO, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230:808-819.
8. Hemming AW, Reed AI, Fujita S, et al. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005;241:693-702.
9. Klempnauer J, Ridder GJ, Werner M, et al. What constitutes long-term survival after surgery for hilar cholangiocarcinoma? Cancer. 1997;79:26-34.
10. Kamada T, Saitou H, Takamura A, et al. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34:767-774.
11. Gonzalez Gonzalez D, Gouma DJ, Rauws EA, et al. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol. 1999;10(Suppl 4):215-220.
12. Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg. 2003;27:173-179.
13. Morganti AG, Trodella L, Valentini V, et al. Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:913-919.
14. Ben-Josef E, Normolle D, Emsinger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739-8747.
15. Campos LT, Alvarez RH, Sanford DB, et al. Gemcitabine and capecitabine in advanced pancreatic cancer and solid tumours. A single institution experience. Proc Am Soc Clin Oncol. 2001;20:A2315.
16. Knox JJ, Hedley D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23:2332-2338.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst. 2000;9:205-216.
18. Ortner MA, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125:1355-1363.
19. Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut. 2005;54:1194-1202.
20. Neuhaus P, Oettle H, Post S, et al. A randomised, prospective, multicenter, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. Proc Am Soc Clin Oncol. 2005;24:A4013.
21. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782.
22. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg. 1995;221:788-797.
23. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful in gallbladder carcinoma? Cancer. 2002;95:1685-1695.
24. Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689-1700.
25. Todoroki T, Kawamoto T, Koike N, et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg. 2000;87:306-131.
26. Kelley ST, Bloomston M, Serafini F, et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg. 2004;70:743-748.
27. Nordback IH, Pitt HA, Coleman J, et al. Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation. Surgery. 1994;115:597-603.
28. Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet. 1994;344:1655-1660.
29. Nehls O, Oettle H, Hartmann JT, et al. A multicenter phase II study of capecitabine plus oxaliplatin (CapOx) in advanced biliary system adenocarcinomas. Proc Am Soc Clin Oncol. 2004;23:A4091.
30. Kornek GV, Schuell B, Laengle F, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial. Ann Oncol. 2004;15:478-483.
31. Reyes-Vidal JM, Gallardo J, et al. Gemcitabine and cisplatin in the treatment of patients with unresectable or metastatic gallbladder cancer: results of the phase II GOCCHI study 2000-13. Proc Am Soc Clin Oncol. 2003;22:A1095.
32. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339-1343.
33. Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol. 1997;15:947-954.
34. Sobin LH, Wittekind C. UICC: TNM Classification of Malignant Tumours. New York: Wiley-Liss Press, 2002.